N-adamantan-1-yl-N',N''-bis-(1,1,2,2-tetramethyl-propyl)-[1,3,5]triazine-2,4,6-triamine | 72822-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N-adamantan-1-yl-N',N''-bis-(1,1,2,2-tetramethyl-propyl)-[1,3,5]triazine-2,4,6-triamine
• 英文别名: 6-N-(1-adamantyl)-2-N,4-N-bis(2,3,3-trimethylbutan-2-yl)-1,3,5-triazine-2,4,6-triamine
• CAS: 72822-51-6
• 化学式: C₂₇H₄₈N₆
• 分子量: 456.718
• InChiKey: CRQQNARYVUULQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  74.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• 2,4,6-Tris-(substituted-amino)-S-triazines, process for their preparation and pharmaceutical compositions containing them
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0005586A1

  公开（公告）日：1979-11-28

  The present invention provides a novel 2,4,6-tris- (substituted-amino)-s-triazines which are useful in medicine, more especially as anti-inflammatory agents and as inhibitors of the progressive joint deterioration characteristic of arthritic disease. The compounds of the invention may be represented by the formula: or a pharmaceutically acceptable acid-addition or quaternary ammonium salt thereof; wherein R, is alkylamino having from 4 to 8 carbon atoms, inclusive, 1-adamantyl-amino, 2-adamantylamino, exo [2.2.1] norbornylamino, endo- [2.2.1] norbornylamino, 3-azabicyclo [3.2.1.] octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] octyl, 3-azabicyclo [3.3.1] -nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] -nonyl, 3-azabicyclo [3.2.2] -nonyl or endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl; R2 is 1-adamantylamino, 2-adamantylamino, exo [2.2.1] norbornylamino, endo- [2.2.1] norbornylamino, 3-azabicyclo [3.2.1] octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] octyl, 3-azabicyclo [3.3.1] -nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] -nonyl, 3-azabicyclo [3.2.2] nonyl or endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl; R3 is hydrogen or alkyl having up to 4 carbon atoms; R4 is 2-(2-pyridyl)ethyl, alkyl having from 4 to 8 carbon atoms, inclusive, phenyl, monohalo(F, Cl, Br)phenyl, 1-adamantyl, 2-adamantyl, ex- o[2.2.1]norbornyl, endo[2.2.1]norbornyl or a monovalent moiety of the formula: wherein Q is a divalent moiety of the formulae: Rs is alkyl having up to 4 carbon atoms, R6 is alkyl having up to 4 carbon atoms or R5 and R6 taken together with their associated N(itrogen) is piperidino, morpholino, pyrrolidino or thiomorpholino; with the proviso that when R4 is alkyl, adamantyl or norbornyl then R3 must be hydrogen; or R3 and R4 taken together with their associated N(itrogen) is 3-azabicyclo [3.2.1] -octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] cotyl, 3-azabicyclo [3.2.1] nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] nonyl, 3-azabicyclo [3.2.2] nonyl, endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl, pyrrolidino, piperidino, hexamethyleneimino, heptamethyleneimino or a monovalent moiety of the formula: wherein R is hydrogen, alkyl having up to 4 carbon atoms, phenyl, p-methoxyphenyl or carboalkoxy having up to 4 carbon atoms.

  本发明提供了一种新型的 2,4,6-三-（取代-氨基）-s-三嗪类化合物，该化合物可用于医药，特别是作为抗炎剂和关节炎疾病特有的关节逐渐退化的抑制剂。本发明的化合物可由式表示： 或其药学上可接受的酸加成盐或季铵盐；其中 R，是具有 4 至 8 个碳原子的烷基氨基，包括 1-金刚烷基氨基、2-金刚烷基氨基、外[2.2.1]降冰片烷基氨基、内[2.2.1]降冰片烷基氨基、3-氮杂双环[3.2.1.] 辛基，1,8,8-三甲基-3-氮杂双环 [3.2.1] 辛基，3-氮杂双环 [3.3.1] 壬基，9-氮杂双环 [3.3.1] 壬基，2-氮杂双环 [3.2.2]-壬基、3-氮杂双环[3.2.2]-壬基或内向-3-羟基-8-氮杂双环[3.2.1]辛-8-基；R2 是 1-金刚烷基氨基、2-金刚烷基氨基、外向 [2.2.1]降冰片酰胺基、内[2.2.1]降冰片酰胺基、3-氮杂双环[3.2.1]辛基、1,8,8-三甲基-3-氮杂双环[3.2.1]辛基、3-氮杂双环[3.3.2.1]壬基、9-氮杂双环[3.3.1]壬基、2-氮杂双环[3.2.2]壬基、3-氮杂双环[3.2.2]壬基或内-3-羟基-8-氮杂双环[3.2.1]辛-8-基；R3 是氢或最多具有 4 个碳原子的烷基；R4 是 2-(2-吡啶基)乙基、具有 4 至 8 个碳原子的烷基（包括 4 个）、苯基、单卤代(F、Cl、Br)苯基、1-金刚烷基、2-金刚烷基、前邻[2.2.1]降冰片烷基、内邻[2.2.1]降冰片烷基或式中的一价分子： 其中 Q 是式中的二价分子： Rs 是具有多达 4 个碳原子的烷基，R6 是具有多达 4 个碳原子的烷基，或 R5 和 R6 连同它们的相关 N（它基）是哌啶基、吗啉基、吡咯烷基或硫代吗啉基；但当 R4 是烷基、金刚烷基或降冰片基时，R3 必须是氢；或 R3 和 R4 连同它们的相关 N（它基）是 3- 氮杂双环 [3.2.1]辛基、1,8,8-三甲基-3-氮杂双环[3.2.1]子基、3-氮杂双环[3.2.1]壬基、9-氮杂双环[3.3.1]壬基、2-氮杂双环[3.2.2]壬基、3-氮杂双环[3.2.2]壬基、内-3-羟基-8-氮杂双环[3.2.1]辛-8-基、吡咯烷基、哌啶基、六亚甲基亚氨基、七亚甲基亚氨基或式中的一价分子： 其中 R 是氢、最多 4 个碳原子的烷基、苯基、对甲氧基苯基或最多 4 个碳原子的羧基烷氧基。